Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland
CGP affects the treatment strategies for NSCLC. Nearly half of our entire cohort had a genetic alteration eligible for approved targeted therapies. Besides these findings, CGP provides additional data to assess treatment decisions and outcomes, including co-occurring genetic alterations and TMB. In real-world clinical practice, the practical application of this information can be restricted by the varying unavailability of optimal treatments.
Authors
- Toomas Uibu
- Arja Jukkola‐Vuorinen (ORCID: https://orcid.org/0000-0002-6107-1764)
- Maarit Tuulikki Barlund (ORCID: https://orcid.org/0000-0002-1469-5654)
- Jarkko Ahvonen (ORCID: https://orcid.org/0000-0003-4335-5242)
- Mauri Keinänen
- Matti Nykter (ORCID: https://orcid.org/0000-0001-6956-2843)
- Vidal Fey (ORCID: https://orcid.org/0000-0003-1388-5904)
- Kirsi Hormalainen (ORCID: https://orcid.org/0009-0003-1753-1350)
- Kaisa Marttila
Institutions
- Tampere University (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
- Fimlab (Finland) (FI)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-09-28
- DOI
- https://doi.org/10.1002/cam4.71250
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tampereen Yliopisto
- Tampereen Tuberkuloosisäätiö